Synthesis and Biological Evaluation of a Paclitaxel Immunoconjugate

  • Ahmad Safavy
  • Kevin P.
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 109)


Targeted cancer therapy is a promising strategy for the treatment of this disease. In this approach, a cytotoxic agent (CA), such as a drug or a radionuclide, is attached, usually covalently, to a “ targeting” vehicle (TV), which in turn is capable of recognizing specific receptor motifs on the surface of the tumor cells. Once administered systemically, the construct would localize on the tumor through the TV moiety and would release the CA cargo, resulting in the destruction of the malignant tissue. Small-molecule peptides as well as monoclonal antibodies have been used as TVs. The synthesis, antigen binding, and cytotoxicity of a covalent conjugate of the anticancer drug paclitaxel (taxol) to the anti-epidermal growth factor receptor (EGFR) monoclonal antibody C225 (IMC-C225; Erbitux®, ImClone Systems, Somerville, NJ) are described in this chapter to illustrate the methods used for the construction and in vitro evaluation of these conjugates.

Key Words

Paclitaxel, taxol C225 monoclonal antibody immunoconjugates targeted therapy drug delivery tumor targeting 


  1. 1.
    Rowinsky, E. K. and Donehower, R. C. (1995) Paclitaxel (taxol). N. Engl. J. Med. 332, 1004–1014.PubMedCrossRefGoogle Scholar
  2. 2.
    Donehower, R. C., Rowinsky, E. K., Grochow, L. B., Longnecker, S. M., and Ettinger, D. S. (1987) Phase I trial of taxol in patients with advanced cancer. Cancer Treat. Rep. 71, 1171–1177.PubMedGoogle Scholar
  3. 3.
    Khayat, D., Antoine, E. C., and Coeffic, D. (2000) Taxol in the management of cancers of the breast and the ovary. Cancer Invest. 18, 242–260.PubMedCrossRefGoogle Scholar
  4. 4.
    Goldspiel, B. R. (1997) Clinical overview of the taxanes. Pharmacotherapy 17, 110S–125S.PubMedGoogle Scholar
  5. 5.
    Safavy, A. (2001) Taxane derivatives for targeted therapy of cancer. US patent no. 6.191.290.Google Scholar
  6. 6.
    Sridhar, S. S., Seymour, L., and Shepherd, F. A. (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 4, 397–406.PubMedCrossRefGoogle Scholar
  7. 7.
    Kies, M. S. and Harari, P. M. (2002) Cetuximab (Imclone/Merck/Bristol-Myers Squibb). Curr. Opin. Investig. Drugs 3, 1092–1100.PubMedGoogle Scholar
  8. 8.
    Goldstein, N. I., Prewett, M., Zuklys, K., Rockwell, P., and Mendelsohn, J. (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1, 1311–1318.PubMedGoogle Scholar
  9. 9.
    Naramura, M., Gillies, S. D., Mendelsohn, J., Reisfeld, R. A., and Mueller, B. M. (1993) Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol. Immunother. 37, 343–349.PubMedCrossRefGoogle Scholar
  10. 10.
    Thompson, D. M. and Gill, G. N. (1985) The EGF receptor: structure, regulation and potential role in malignancy. Cancer Surv. 4, 767–788.PubMedGoogle Scholar
  11. 11.
    Schlessinger, J. (1988) The epidermal growth factor receptor as a multi-functional allos-teric protein. Biochem. 27, 3119–3123.CrossRefGoogle Scholar
  12. 12.
    Carpenter, G. and Cohen, S. (1979) Epidermal growth factor. Ann. Rev. Biochem. 48, 193–216.PubMedCrossRefGoogle Scholar
  13. 13.
    Pathak, M. A., Matrisian, L. M., Magun, B. E., and Salmon, S. E. (1982) Effect of epidermal growth factor on clonogenic growth of primary human tumor cells. Int. J. Cancer 30, 745–750.PubMedCrossRefGoogle Scholar
  14. 14.
    Singletary, S. E., Baker, F. L., Spitzer, G., et al. (1987) Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res. 47, 403–406.PubMedGoogle Scholar
  15. 15.
    Safavy, A., Raisch, K. P., Khazaeli, M. B., Buchsbaum, D. J., and Bonner, J. A. (1999) Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes. J. Med. Chem. 42, 4919–4924.PubMedCrossRefGoogle Scholar
  16. 16.
    Safavy, A., Bonner, J. A., Waksal, H., et al. (2003) Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug. Chem. 14, 302–310.PubMedCrossRefGoogle Scholar
  17. 17.
    Deutsch, H., Glinski, J., Hernandez, M., et al. (1989) Synthesis of congeners and prodrugs: water soluble prodrugs of taxol with potent antitumor activity. J. Med. Chem. 32, 788–792.PubMedCrossRefGoogle Scholar
  18. 18.
    Wilbur, D. S. (1992) Radiohalogenation of proteins: An overview of radionuclides, labeling methods, and reagents for conjugate labeling. Bioconjug. Chem. 3, 433–470.PubMedCrossRefGoogle Scholar
  19. 19.
    Neises, B. and Steglich, W. (1978) Simple method for the esterification of carboxylic acids. Angew. Chem. Int. Enl. 17, 522–523.CrossRefGoogle Scholar
  20. 20.
    Lloyd-Williams, P., Albericio, F., and Giralt, E. (1997) Chemical Approaches to the Synthesis of Peptides. CRC, Boca Raton, FL.Google Scholar
  21. 21.
    Siegel, M. M., Hollander, I. J., Hamann, P. R., et al. (1991) Matrix-assisted uv-laser des-orption/ionization mass spectrometric analysis of monoclonal antibodies for the determination of carbohydrate, conjugated chelator, and conjugated drug content. Anal. Chem. 63, 2470–2481.PubMedCrossRefGoogle Scholar
  22. 22.
    Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265–275.PubMedGoogle Scholar
  23. 23.
    Fenselau, C. (1997) MALDI MS and strategies for protein analysis. Anal. Chem. 69, 661A–665A.PubMedGoogle Scholar
  24. 24.
    Saleh, M. N., Raisch, K. P., Stackhouse, M. A., et al. (1999) Combined modality therapy of A-431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother. Radiopharm. 14, 451–463.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2005

Authors and Affiliations

  • Ahmad Safavy
    • 1
  • Kevin P.
    • 1
  1. 1.Division of Radiation Biology, Department of Radiation Oncology, and Comprehensive Cancer CenterUniversity of Alabama at BirminghamBirmingham

Personalised recommendations